To include your compound in the COVID-19 Resource Center, submit it here.
Oncolytics said the Gynecologic Oncology Group (GOG) completed enrollment of about 150 patients in an open-label, U.S. Phase II
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury